Journal: Nature Immunology
Article Title: The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology
doi: 10.1038/s41590-024-01756-6
Figure Lengend Snippet: a , absolute counts of cytokines produced by microglia, monocytes, Ly6C − myeloid cells, CD4 + T cells, and astrocytes in the spinal cord or brain of vehicle or rmHB-EGF treated mice (starting symptom onset). n = 4 per group. b , abundance (% of live) of major immune cell populations in draining axillary lymph nodes of mice intranasally treated with vehicle (n = 7) or recombinant HB-EGF (rmHB-EGF, n = 5) starting at symptom onset. c , abundance (% of live) of CNS-resident and CNS-infiltrating cell types in EAE mice intranasally treated with vehicle or recombinant mouse HB-EGF (rmHB-EGF) starting at symptom onset. DC, dendritic cells, Endo, endothelial cells; OPCs, oligodendrocyte progenitor cells; OLCs, oligodendrocyte lineage cells. n = 8 per group. d , relative expression (% of parent) of cytokines produced by microglia, monocytes, Ly6C − myeloid cells, CD4 + T cells, and astrocytes in the CNS of vehicle or rmHB-EGF treated mice. n = 8 per group. e , gating strategy used for the analysis of splenic cell types by high dimensional flow cytometry. f , concentration of soluble HB-EGF (sHB-EGF) in sera of vehicle- or rmHB-EGF treated mice. n = 5 per group. g , abundance of cell populations (% of live) in spleens of mice treated with vehicle or rmHB-EGF. n = 8 per group. h , relative expression (% of parent) of cytokines produced by monocytes, Ly6C- myeloid cells, CD4 + and CD8 + T cells, in spleens of vehicle or rmHB-EGF treated mice. n = 8 per group. i , frequency of T H 1 (IFN − γ + ) and T H 17 (IL-17 + ) CD4 + T cells in the CNS and spleen of mice that were intranasally treated with vehicle or rmHB-EGF starting at peak of disease. n = 6 per group. Data shown as mean ± SD. Two-way ANOVA with Sidak’s multiple comparisons test in ( a - d , g , h ). Unpaired t-test in ( f , i ).
Article Snippet: During the first 24 h, 10 ng ml −1 recombinant rat platelet-derived growth factor-AA (PDGF-AA; R&D, no. 1055-AA-050) and 10 ng ml −1 recombinant human bFGF (R&D, no. 233-FB) were additionally supplemented.
Techniques: Produced, Recombinant, Expressing, Flow Cytometry, Concentration Assay
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
